Has the mortality rate from acute myocardial infarction fallen substantially in recent years?

[1]  H. Krumholz,et al.  Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. , 1998, JAMA.

[2]  W. Rogers,et al.  Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. , 2000, Journal of the American College of Cardiology.

[3]  T. Bowker,et al.  Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK) , 2000, European heart journal.

[4]  Norris Rm,et al.  Fatality outside hospital from acute coronary events in three British health districts, 1994-5 , 1998 .

[5]  H. Tunstall-Pedoe,et al.  Population versus clinical view of case fatality from acute coronary heart disease: results from the WHO MONICA Project 1985-1990. Multinational MONItoring of Trends and Determinants in CArdiovascular Disease. , 1997, Circulation.

[6]  W. Kannel,et al.  Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. , 1984, The New England journal of medicine.

[7]  B Lown,et al.  The Coronary Care Unit: New Perspectives and Directions , 1967 .

[8]  H. Tunstall-Pedoe,et al.  Myocardial Infarction and Coronary Deaths in the World Health Organization MONICA Project: Registration Procedures, Event Rates, and Case‐Fatality Rates in 38 Populations From 21 Countries in Four Continents , 1994, Circulation.

[9]  A. Hall,et al.  Poor prognosis of patients presenting with symptomatic myocardial infarction but without chest pain , 2001, Heart.

[10]  A Coulter,et al.  Patient choice modules for summaries of clinical effectiveness: a proposal , 2001, BMJ : British Medical Journal.

[11]  H. White,et al.  Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial , 2001, The Lancet.

[12]  P. Armstrong,et al.  Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. , 2001 .

[13]  C. Fry,et al.  Science of urinary incontinence Report of a Meeting of Physicians and Scientists, University College London , 1994, The Lancet.

[14]  Johan Herlitz,et al.  Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[15]  P. Zoll,et al.  Termination of ventricular fibrillation in man by externally applied electric countershock. , 1956, The New England journal of medicine.

[16]  Assent investigators.  Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction , 2001, The Lancet.

[17]  W. B. Kouwenhoven,et al.  Closed-chest cardiac massage. , 1960, JAMA.

[18]  J S Alpert,et al.  The Impact of Age on the Incidence and Prognosis of Initial Acute Myocardial Infarction: The Worcester Heart Attack Study , 1989, American heart journal.